A CRISPR / Cas9 delivery system and its preparation method and application

Through the method of combining superparamagnetic nanoparticles and cationic polymers, the loading and targeting problems of CRISPR/Cas9 plasmid are solved, and the efficient loading and specific enrichment of CRISPR/Cas9 plasmid is achieved, providing MRI traceability function and an efficient gene therapy platform.

CN115068631BActive Publication Date: 2024-12-03INSTITUTE OF PROCESS ENGINEERING CHINESE ACADEMY OF SCIENCES
View PDF 21 Cites 0 Cited by

Patent Information

Application Number
CN202110262193.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-03-10
Publication Date
2024-12-03
Estimated Expiration
2041-03-10

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently load the CRISPR/Cas9 plasmid and achieve its specific enrichment in lesions, and lacks MRI tracing function and targeting, which limits its application in gene therapy.

Method used

Superparamagnetic nanoparticles are used to combine cationic polymer polymers and targeted molecules to effectively load CRISPR/Cas9 plasmids by electrostatic adsorption, and modify the surface of superparamagnetic nanoparticles through covalent ligation to achieve targeting and MRI traceability.

Benefits of technology

The efficient loading and specific enrichment of CRISPR/Cas9 plasmids are achieved, which enhances gene editing efficiency, and provides an efficient drug delivery platform through MRI tracer function, especially suitable for the treatment of brain diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115068631B_ABST
    Figure CN115068631B_ABST
Patent Text Reader

Abstract

The present invention relates to a CRISPR / Cas9 delivery system and a preparation method and application thereof. The delivery system comprises superparamagnetic nanoparticles, cationic polymers, targeting molecules and CRISPR / Cas9 plasmids, wherein the cationic polymers are attached to the superparamagnetic nanoparticles, and the targeting molecules and the CRISPR / Cas9 plasmids are respectively combined with the cationic polymers. The superparamagnetic nanoparticles enable the delivery system to be tracked in real time by nuclear magnetic resonance imaging, and the cationic polymers are attached to the surface of the superparamagnetic nanoparticles and can be combined with the targeting molecules, so that the delivery system has targeting, and electrostatic adsorption occurs with the CRISPR / Cas9 plasmids, thereby efficiently loading the CRISPR / Cas9 plasmids.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of biotechnology and relates to a CRISPR / Cas9 delivery system and a preparation method and application thereof, and in particular to a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function and a preparation method and application thereof. Background Art

[0002] CRISPR / Cas9 is a technology that uses RNA to guide the Cas9 nuclease to perform specific DNA modifications on targeted genes. Gene editing based on CRISPR / Cas9 technology requires two important elements: gRNA and Cas9 endonuclease. The CRISPR plasmid is a gene that expresses the Cas9 protein and transcribes the gRNA and connects it to a universal plasmid. Through cell transfection, the plasmid is transfected into the target cell to express the Cas9 protein and gRNA. The two form RNPs, which recognize the target sequence and cut it under the traction of the gRNA, and then complete the gene editing process. However, due to the large molecular weight of the CRISPR plasmid and the difficulty of loading, the application of CRISPR is limited. Therefore, a delivery system that can efficiently load CRISPR is needed to help CRISPR work better.

[0003] The visually tracing CRISPR gene delivery system has important guiding significance for CRISPR treatment. Among them, magnetic resonance imaging (MRI) is one of the most widely used imaging examination methods, which can show the structure of systemic tissues and organs and the state of lesions with the help of magnetic resonance contrast agents. The MRI-guided CRISPR delivery system can help diagnose diseases and guide the construction of delivery systems, and is of great value for the clinical application of CRISPR.

[0004] CN103405790A discloses a method for preparing superparamagnetic particles modified in situ by polymers and its use, wherein superparamagnetic particles are coated in polyethylene glycol-polyacrylic acid block copolymer (PEG-PAA) to obtain superparamagnetic particles with PEG molecules modified on the surface. Although this invention can solve the problem of superparamagnetic particle modification and improve the stability of superparamagnetic particles, the superparamagnetic particles coated with PEG-PAA are neutral and have no loading capacity or targeting ability for negatively charged CRISPR gene drugs.

[0005] CN103690971A discloses a method for preparing superparamagnetic particles with rheumatoid arthritis site targeting, using the high affinity of folic acid to macrophages expressing folate receptors on the surface to achieve targeted imaging, providing a contrast agent that can specifically image rheumatoid arthritis in magnetic resonance imaging, and the magnetic resonance contrast agent uses a chemical connection method to couple polyethylene glycol-b-polyacrylic acid modified superparamagnetic particles with folic acid molecules to obtain a magnetic resonance imaging contrast agent for imaging rheumatoid arthritis sites with a particle size of about 20nm, high specificity and strong contrast effect. Although this invention can solve the problem of superparamagnetic particle targeting, it still does not have the loading capacity for CRISPR gene drugs.

[0006] CN110215522A discloses a CRISPR / Cas9 delivery system and its preparation method and application. The delivery system includes a gold nanocluster core, a CRISPR / Cas9 gene editing system attached to the gold nanocluster, and a liposome shell; the CRISPR / Cas9 gene editing system includes sgRNA and Cas9 protein; the Cas9 protein is connected to a nuclear localization signal peptide, thereby achieving efficient, specific and nuclear-targeted delivery of CRISPR / Cas9, but does not have a tracing function.

[0007] In summary, providing a CRISPR / Cas9 delivery system with tracing function and high targeting is of great significance in the field of visual tracing gene therapy. Summary of the invention

[0008] In view of the deficiencies of the prior art and actual needs, the present invention provides a CRISPR / Cas9 delivery system and a preparation method and application thereof. The CRISPR / Cas9 delivery system can efficiently load CRISPR / Cas9 plasmids, has targeting properties, can specifically enrich in lesions, and also has a high relaxation rate, thereby providing an efficient drug delivery platform for visually traceable gene therapy.

[0009] To achieve the above object, the present invention adopts the following technical solutions:

[0010] In a first aspect, the present invention provides a CRISPR / Cas9 delivery system, which includes superparamagnetic nanoparticles, cationic polymers, targeting molecules and CRISPR / Cas9 plasmids, wherein the cationic polymers are attached to the superparamagnetic nanoparticles, and the targeting molecules and the CRISPR / Cas9 plasmids are respectively combined with the cationic polymers.

[0011] In the delivery system of the present invention, superparamagnetic nanoparticles can be used as contrast agents to improve the relaxation rate of the delivery system, so that the delivery system can be traced in real time through nuclear magnetic resonance imaging; cationic high molecular polymers can be coordinated and connected with superparamagnetic nanoparticles, attached to the surface of superparamagnetic nanoparticles, and can be combined with targeting molecules, so that the delivery system has targeting, and electrostatic adsorption occurs with CRISPR / Cas9 plasmids, thereby efficiently loading CRISPR / Cas9 plasmids.

[0012] In addition, the delivery system of the present invention can directly load CRISPR / Cas9 plasmids instead of gRNA and Cas9 endonuclease, and can be enriched specifically in lesions and express gRNA and Cas9 endonuclease to complete the gene editing process. Therefore, the gRNA and Cas9 endonuclease can be prevented from being destroyed during the delivery process, thereby efficiently realizing the gene editing process.

[0013] Preferably, the cationic high molecular polymer comprises dopamine-polylysine-polyethylene glycol-maleimide.

[0014] Preferably, the targeting molecule comprises a polypeptide derived from rabies virus glycoprotein.

[0015] Preferably, the rabies virus glycoprotein-derived polypeptide comprises the amino acid sequence shown in SEQ ID NO:1.

[0016] SEQ ID NO: 1:

[0017] YTIWMPENPRPGTPCDIFTNSRGKRASNG.

[0018] Preferably, the targeting molecule is modified with thiol groups.

[0019] In the present invention, a polypeptide of a 29-amino acid sequence derived from rabies virus glycoprotein (named RVG29) can be used as a targeting molecule (mainly a brain targeting molecule), and the thiol-modified RVG29 is mixed with superparamagnetic particles modified with a cationic polymer, and the thiol group reacts with the cationic polymer (maleimide group in dopamine-polylysine-polyethylene glycol-maleimide) to obtain superparamagnetic particles with brain targeting function.

[0020] In a second aspect, the present invention provides a method for preparing the CRISPR / Cas9 delivery system as described in the first aspect, the method comprising the following steps:

[0021] (1) mixing a cationic polymer with superparamagnetic nanoparticles and reacting them to obtain superparamagnetic particles modified with the cationic polymer;

[0022] (2) mixing the cationic polymer-modified superparamagnetic particles with targeting molecules to react and obtain superparamagnetic particles with targeting function;

[0023] (3) Mixing the CRISPR / Cas9 plasmid with the superparamagnetic particles with targeting function to react and obtain the CRISPR / Cas9 delivery system.

[0024] Preferably, the mass ratio of the cationic high molecular polymer to the superparamagnetic nanoparticles in step (1) is 1:(5-20), including but not limited to 1:5, 1:6, 1:7, 1:8, 1:10, 1:15, 1:16, 1:17, 1:18, 1:19 or 1:20, preferably 1:(5-10).

[0025] Preferably, the cationic high molecular polymer in step (1) is dissolved in dimethyl sulfoxide solvent, and the superparamagnetic nanoparticles in step (1) are dissolved in chloroform solvent.

[0026] Preferably, the reaction temperature in step (1) is 20-30°C, including but not limited to 21°C, 22°C, 23°C, 25°C, 26°C, 28°C or 29°C.

[0027] Preferably, the reaction time of step (1) is 2 to 6 hours, including but not limited to 2.5 hours, 3 hours, 4 hours, 5 hours or 5.5 hours.

[0028] Preferably, after the reaction in step (1) is completed, the solvent is blown dry in a protective gas, and placed in a vacuum drying oven to drain the solvent, and finally dispersed in an aqueous solution.

[0029] Preferably, the protective gas may be nitrogen.

[0030] Preferably, the mass ratio of the cationic high molecular polymer modified superparamagnetic particles to the targeting molecules in step (2) is (10-100):1, including but not limited to 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1, preferably (30-100):1, and further preferably (30-60):1.

[0031] Preferably, the solvent for the reaction in step (2) is water.

[0032] Preferably, the reaction temperature in step (2) is 20-30°C, including but not limited to 21°C, 22°C, 23°C, 25°C, 27°C, 28°C or 29°C.

[0033] Preferably, the reaction time of step (2) is 24 to 48 hours, including but not limited to 25 hours, 26 hours, 27 hours, 28 hours, 30 hours, 35 hours, 40 hours, 42 hours, 44 hours, 46 hours or 47 hours.

[0034] Preferably, after step (2), unreacted impurities need to be removed.

[0035] Preferably, the removal method is dialysis.

[0036] Preferably, the dialysis method is to place the reaction product into a dialysis bag with a molecular weight cutoff of 10,000 and perform dialysis with water.

[0037] Preferably, in step (3), the mass ratio of the CRISPR / Cas9 plasmid to the superparamagnetic particles with targeting function is (0.1-10):1, including but not limited to 0.1:1, 0.5:1, 1:1, 2:1, 4:1, 8:1 or 10:1.

[0038] Preferably, the reaction temperature in step (3) is 20-30°C, including but not limited to 21°C, 22°C, 23°C, 25°C, 27°C, 28°C or 29°C.

[0039] Preferably, the reaction time of step (3) is 10 to 40 min, including but not limited to 11 min, 12 min, 13 min, 14 min, 15 min, 20 min, 30 min, 31 min, 32 min, 35 min, 36 min or 38 min.

[0040] Preferably, the method further comprises the step of preparing a cationic high molecular polymer.

[0041] Preferably, the method for preparing the cationic high molecular polymer comprises the following steps:

[0042] (1') using benzyloxycarbonyl-protected lysine to react under the action of triphosgene to obtain a lysine monomer;

[0043] (2') using dopamine hydrochloride as an initiator to initiate a ring-opening reaction of the lysine monomer obtained in step (1') and polymerize to form dopamine-polylysine;

[0044] (3') mixing active ester-polyethylene glycol-maleimide with the dopamine-polylysine obtained in step (2') to react to obtain dopamine-polylysine-polyethylene glycol-maleimide;

[0045] (4') In an acidic environment, removing the benzyloxycarbonyl protecting group of lysine from the dopamine-polylysine-polyethylene glycol-maleimide synthesized in step (3') to obtain the cationic high molecular polymer.

[0046] Preferably, step (1') is to mix benzyloxycarbonyl-protected lysine and anhydrous ethyl acetate, and then add triphosgene to react to obtain a lysine monomer.

[0047] Preferably, the ratio of the benzyloxycarbonyl-protected lysine to anhydrous ethyl acetate is 1 g:(30-100) mL, including but not limited to 1 g:31 mL, 1 g:32 mL, 1 g:33 mL, 1 g:40 mL, 1 g:50 mL, 1 g:60 mL, 1 g:70 mL, 1 g:80 mL, 1 g:90 mL or 1 g:95 mL.

[0048] Preferably, the mass ratio of the benzyloxycarbonyl-protected lysine to triphosgene is (1-3):1, including but not limited to 1:1, 1:2 or 1:3.

[0049] Preferably, the reaction temperature in step (1') is 60-75°C, including but not limited to 61°C, 62°C, 63°C, 64°C, 65°C, 66°C, 70°C, 71°C, 72°C, 73°C or 74°C.

[0050] Preferably, the reaction time of step (1') is 4 to 5 h, including but not limited to 4 h, 4.5 h or 5 h.

[0051] Preferably, after the reaction system in step (1') becomes clear and transparent, rotary evaporation (rotary evaporation) is performed to remove the ethyl acetate solution.

[0052] Preferably, an excess amount of n-hexane is added to the system after the rotary evaporation, and then the system is filtered and placed in a vacuum drying oven for drying.

[0053] Preferably, step (2') is to mix dopamine hydrochloride, lysine monomer and triethylamine in anhydrous N,N-dimethylformamide and react to obtain dopamine-polylysine.

[0054] Preferably, the mass ratio of the lysine monomer to dopamine hydrochloride is (1-100):1, including but not limited to 2:1, 4:1, 8:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1, preferably (60-100):1, and more preferably (80-100):1.

[0055] Preferably, the molar ratio of triethylamine to dopamine hydrochloride is (1-3):1, including but not limited to 1:1, 2:1 or 3:1.

[0056] Preferably, the degree of polymerization of the dopamine-polylysine polymer is any integer from 1 to 500, including but not limited to 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 38, 40, 44, 48, 50, 60, 70, 80, 90, 100, 120, 140, 160, 180, 200, 250, 300, 350, 400, 450, 480 or 490, preferably any integer from 20 to 300, and more preferably any integer from 50 to 200.

[0057] Preferably, the reaction temperature in step (2') is 40-50°C, including but not limited to 40°C, 42°C, 44°C, 46°C, 48°C or 50°C.

[0058] Preferably, the reaction time of step (2') is 20 to 25 h, including but not limited to 20 h, 21 h, 22 h, 23 h, 24 h or 25 h.

[0059] Preferably, after the reaction in step (2') is completed, the solvent and unreacted impurities are removed.

[0060] Preferably, the removal method is dialysis.

[0061] Preferably, the dialysis method comprises: placing the reaction product in a dialysis bag with a molecular weight cutoff of 2000, dialyzing with an organic solvent first, and then switching to water for dialysis.

[0062] Preferably, the organic solvent is N,N-dimethylformamide.

[0063] Preferably, in step (3'), the molar ratio of the active ester-polyethylene glycol-maleimide to dopamine-polylysine is (1-3):1, including but not limited to 1:1, 2:1 or 3:1.

[0064] Preferably, the solvent for the reaction in step (3') is N,N-dimethylformamide.

[0065] Preferably, the reaction temperature in step (3') is 20-30°C, including but not limited to 21°C, 22°C, 23°C, 25°C, 27°C, 28°C or 29°C.

[0066] Preferably, the acidic environment in step (4') is a mixed solution of trifluoroacetic acid and hydrobromic acid.

[0067] Preferably, the mass ratio of trifluoroacetic acid to hydrobromic acetic acid is (5-20):1, including but not limited to 5:1, 6:1, 7:1, 8:1, 10:1, 12:1, 15:1, 16:1, 18:1, 19:1 or 20:1, preferably (5-10):1.

[0068] Preferably, the mass ratio of the hydrobromic acid to dopamine-lysine-polyethylene glycol-maleimide is (1-100):1, including but not limited to 2:1, 4:1, 8:1, 10:1, 20:1, 30:1, 40:1, 50:1, 60:1, 70:1, 80:1, 90:1 or 100:1, preferably (60-100):1, and more preferably (80-100):1.

[0069] Preferably, the temperature for removing the benzyloxycarbonyl protecting group of lysine in step (4') is 20-30°C, including but not limited to 21°C, 22°C, 23°C, 25°C, 27°C, 28°C or 29°C.

[0070] Preferably, the time for removing the benzyloxycarbonyl protecting group of lysine in step (4') is 1 to 3 hours.

[0071] Preferably, after the reaction in step (4') is completed, the solvent and unreacted impurities are removed.

[0072] Preferably, the removal method is dialysis.

[0073] Preferably, the dialysis method comprises: placing the reaction product in a dialysis bag with a molecular weight cutoff of 2000, dialyzing with an organic solvent first, and then switching to water for dialysis.

[0074] Preferably, the organic solvent is N,N-dimethylformamide.

[0075] Preferably, the method further comprises the step of preparing superparamagnetic nanoparticles.

[0076] Preferably, the method for preparing the superparamagnetic nanoparticles comprises mixing biphenyl-4-carboxylic acid, tris(2,4-pentanedione)iron(III), oleic acid and benzyl ether, and reacting them to obtain superparamagnetic nanoparticles.

[0077] Preferably, the mass ratio of biphenyl-4-carboxylic acid to tris(2,4-pentanedione)iron(III) is (0.5-0.6):1, including but not limited to 0.5:1, 0.55:1 or 0.6:1.

[0078] Preferably, the mass ratio of oleic acid to tris(2,4-pentanedione)iron(III) is (1.7-1.8):1, including but not limited to 1.7:1, 1.75:1 or 1.8:1.

[0079] Preferably, the ratio of the benzyl ether to tri(2,4-pentanedione)iron(III) is (26-27) mL:1 g, including but not limited to 26 mL:1 g, 26.5 mL:1 g or 27 mL:1 g.

[0080] Preferably, the reaction temperature is raised to 110-130°C (for example, 112°C, 114°C, 116°C, 120°C, 122°C, 124°C, 126°C or 128°C), nitrogen is introduced for 10-20 min (for example, 11 min, 12 min, 13 min, 14 min, 16 min, 18 min or 19 min), and the temperature is then raised to 280-300°C (for example, 282°C, 283°C, 284°C, 285°C, 290°C, 292°C, 294°C, 296°C or 298°C).

[0081] Preferably, the reaction time is 1 to 2 hours.

[0082] Preferably, after the reaction is completed, the superparamagnetic nanoparticles are washed with methanol and stored in chloroform.

[0083] As a preferred technical solution, the preparation method of the CRISPR / Cas9 delivery system comprises the following steps:

[0084] (1) biphenyl-4-carboxylic acid, tri(2,4-pentanedione)iron(III), oleic acid and benzyl ether are mixed in a ratio of (0.5-0.6) g:1 g:(1.7-1.8) g:(26-27) mL, the temperature is first raised to 110-130° C., nitrogen is introduced for 10-20 min, and the temperature is then raised to 280-300° C. for reaction for 1-2 h to obtain superparamagnetic nanoparticles;

[0085] (2) mixing benzyloxycarbonyl protected lysine and anhydrous ethyl acetate in a ratio of 1 g: (30-100) mL, and then adding triphosgene, wherein the mass ratio of the benzyloxycarbonyl protected lysine to triphosgene is (1-3):1, and reacting at 60-75° C. for 4-5 hours to obtain a lysine monomer;

[0086] (3) mixing dopamine hydrochloride, lysine monomer and triethylamine in anhydrous N,N-dimethylformamide, wherein the mass ratio of the lysine monomer to dopamine hydrochloride is (1-100):1, and the molar ratio of the triethylamine to dopamine hydrochloride is (1-3):1, and reacting at 40-50° C. for 20-25 hours to obtain dopamine-polylysine;

[0087] (4) in N,N-dimethylformamide, the active ester-polyethylene glycol-maleimide and the dopamine-polylysine are mixed in a molar ratio of (1-3):1, and reacted at 20-30° C. to obtain dopamine-polylysine-polyethylene glycol-maleimide;

[0088] (5) removing the benzyloxycarbonyl protecting group of lysine from the dopamine-polylysine-polyethylene glycol-maleimide in a mixed solution of trifluoroacetic acid and hydrobromic acid in a mass ratio of (5 to 20):1 to obtain the cationic polymer;

[0089] (6) mixing the cationic polymer and the superparamagnetic nanoparticles at a mass ratio of 1:(5-20), reacting at 20-30° C. for 2-6 hours, to obtain superparamagnetic particles modified with the cationic polymer;

[0090] (7) mixing the cationic polymer-modified superparamagnetic particles with the targeting molecules at a mass ratio of (10-100):1, and reacting at 20-30° C. for 24-48 hours to obtain superparamagnetic particles with targeting function;

[0091] (8) Mixing the CRISPR / Cas9 plasmid and the superparamagnetic particles with targeting function at a mass ratio of (0.1-10):1, reacting at 20-30° C. for 10-40 minutes, and obtaining the CRISPR / Cas9 delivery system.

[0092] In a third aspect, the present invention provides a pharmaceutical composition, comprising the CRISPR / Cas9 delivery system described in the first aspect.

[0093] Preferably, the pharmaceutical composition further comprises any one or a combination of at least two of a pharmaceutically acceptable carrier, excipient or diluent.

[0094] In a fourth aspect, the present invention provides a use of the CRISPR / Cas9 delivery system as described in the first aspect and / or the pharmaceutical composition as described in the third aspect in the preparation of a drug for treating a disease.

[0095] Preferably, the disease comprises a brain disease.

[0096] Compared with the prior art, the present invention has the following beneficial effects:

[0097] (1) In the delivery system of the present invention, superparamagnetic nanoparticles enable the delivery system to be tracked in real time by nuclear magnetic resonance imaging. Cationic polymers are attached to the surface of superparamagnetic nanoparticles and can bind to targeting molecules, so that the delivery system has targeting properties and electrostatic adsorption occurs with CRISPR / Cas9 plasmids, thereby efficiently loading CRISPR / Cas9 plasmids. In addition, the gRNA and Cas9 endonuclease can be prevented from being destroyed during the delivery process, thereby efficiently realizing the gene editing process;

[0098] (2) The present invention controllably modifies the surface of each superparamagnetic nanoparticle with a cationic polymer by covalent linkage, so that each superparamagnetic nanoparticle can be loaded with CRISPR / Cas9 plasmid, thereby enhancing the loading efficiency;

[0099] (3) The delivery system of the present invention can efficiently load CRISPR / Cas9 plasmids, and the relaxation efficiency is not less than 450.13mM -1 s -1 , with excellent MRI imaging sensitivity, thus providing an efficient drug delivery platform for visually traceable gene therapy. BRIEF DESCRIPTION OF THE DRAWINGS

[0100] Figure 1 This is a transmission electron microscope (TEM) image of the superparamagnetic nanoparticles obtained in Example 1;

[0101] Figure 2 This is a transmission electron microscopy (TEM) image of the CRISPR / Cas9 delivery system with both MRI imaging function and brain targeting function obtained in Example 1;

[0102] Figure 3 This is the infrared characteristic spectrum of the superparamagnetic nanoparticles before and after modification of the targeting molecules in Example 1;

[0103] Figure 4 It is the agarose gel electrophoresis analysis diagram;

[0104] Figure 5 This is a potential characterization diagram of the CRISPR / Cas9 delivery system with both MRI imaging function and brain targeting function obtained in Example 2 before and after loading the CRISPR / Cas9 plasmid;

[0105] Figure 6 This is a particle size distribution diagram of the CRISPR / Cas9 delivery system with both MRI imaging function and brain targeting function obtained in Example 3;

[0106] Figure 7 This is a relaxation rate diagram of the CRISPR / Cas9 delivery system with both MRI imaging function and brain targeting function obtained in Example 1;

[0107] Figure 8 Magnetic resonance imaging images of the brain of mice before and after injection of the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function obtained in Example 1. The scale bar is 2 mm. DETAILED DESCRIPTION

[0108] To further illustrate the technical means and effects of the present invention, the present invention is further described below in conjunction with the embodiments and drawings. It should be understood that the specific implementation methods described herein are only used to explain the present invention, rather than to limit the present invention.

[0109] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0110] Example 1

[0111] This embodiment provides a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function. The preparation method of the CRISPR / Cas9 delivery system comprises the following steps:

[0112] (1) Preparation of superparamagnetic nanoparticles: 0.400 g of 4-biphenylcarboxylic acid, 0.706 g of iron (III) acetylacetonate, 1.270 g of oleic acid and 19 mL of benzyl ether were mixed together in a three-necked round-bottom flask. The solution was heated to 120°C and kept in a nitrogen environment for 15 min. The mixed solution was then heated to 320°C at a rate of 20°C / min and aged for 90 min. After the solution was cooled, it was washed with methanol. Superparamagnetic nanoparticles with good magnetic properties were selected and dissolved in chloroform. The transmission electron microscopy (TEM) image of the superparamagnetic nanoparticles is shown in FIG. Figure 1 As shown;

[0113] (2) Preparation of lysine monomer: 2 g of Nε-benzyloxycarbonyl-L-lysine (H-Lys(Z)-OH) was dissolved in 80 mL of anhydrous ethyl acetate in a three-necked flask, and the mixture was heated to 75° C. under a nitrogen environment and maintained for 30 min. 1 g of triphosgene was dissolved in 20 mL of anhydrous ethyl acetate and added to the above reaction solution. The reaction was carried out for about 5 h until the solution became clear and transparent. Subsequently, the clear solution was rotary evaporated and precipitated with excess hexane. Finally, the obtained powder was placed in a vacuum drying oven and the water was drained to obtain the product.

[0114] (3) Preparation of dopamine-polylysine: 500 mg of lysine monomer, 5.2 mg of dopamine hydrochloride and 7.53 μL of triethylamine were dissolved in anhydrous N,N-dimethylformamide and reacted at 40° C. in a nitrogen environment for 24 h. The obtained product was dialyzed to remove impurities and freeze-dried to obtain dopamine-polylysine;

[0115] (4) Preparation of dopamine-polylysine-polyethylene glycol-maleimide: 85 mg of dopamine-polylysine with a degree of polymerization of 60 and 11 mg of active ester-polyethylene glycol-maleimide were dissolved in N,N-dimethylformamide solution, reacted at room temperature for 24 h, the obtained product was dialyzed to remove impurities, and freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide;

[0116] (5) Removal of lysine protecting groups from dopamine-polylysine-polyethylene glycol-maleimide: 500 mg of dopamine-polylysine-polyethylene glycol-maleimide was dissolved in 2 mL of trifluoroacetic acid, and then 1441 μL of hydrobromic acid was added. The mixture was reacted at room temperature for 2 h, and chloroform was added. The trifluoroacetic acid was removed by rotary evaporation, and the mixture was dissolved in N,N-dimethylformamide. Impurities were removed by dialysis, and the mixture was freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide with positive charges after the removal of the protecting groups.

[0117] (6) Preparation of superparamagnetic particles modified by cationic polymers: 2 mg of the superparamagnetic particles obtained in step (1) were dissolved in 10 mL of chloroform, 10 mg of the dopamine-polylysine-polyethylene glycol-maleimide with positive charge removed from the protecting group obtained in step (5) was dissolved in 500 μL of dimethyl sulfoxide, the two solutions were mixed, and the mixture was vigorously shaken at room temperature for 4 h. After the reaction was completed, the solvent was dried under nitrogen atmosphere, the mixture was placed in a vacuum drying oven to drain the residual solvent, and 1 mL of aqueous solution was added for re-dissolution to obtain superparamagnetic nanoparticles modified by cationic polymers;

[0118] (7) Preparation of superparamagnetic particles with brain targeting function: 1 mL of the cationic polymer-modified superparamagnetic nanoparticles obtained in step (6) was added with 100 mg of thiol-modified RVG29, and the mixture was reacted at room temperature for 24 h. The product was dialyzed to remove impurities, thereby obtaining superparamagnetic particles with brain targeting function;

[0119] (8) Construction of a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function: 0.25 μg of the superparamagnetic particles with targeting function obtained in step (7) was mixed with 1 μg of CRISPR / Cas9 plasmid (px458 plasmid) and allowed to stand for 30 min to obtain a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function. The transmission electron microscopy (TEM) image is as follows Figure 2 shown.

[0120] Example 2

[0121] This embodiment provides a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function, and its preparation method is as follows:

[0122] (1) Preparation of superparamagnetic nanocubes: 0.400 g of 4-biphenylcarboxylic acid, 0.706 g of iron (III) acetylacetonate, 1.270 g of oleic acid and 19 mL of benzyl ether were mixed in a three-necked round-bottom flask. The solution was heated to 120°C and kept in a nitrogen environment for 15 min, then the mixed solution was heated to 320°C at a rate of 20°C / min and aged for 90 min. After the solution was cooled, the solution was washed with methanol, and superparamagnetic nanoparticles with better magnetic properties were selected and dissolved in chloroform;

[0123] (2) Preparation of lysine monomer: 2 g of H-Lys(Z)-OH was dissolved in 80 mL of anhydrous ethyl acetate in a three-necked flask, and the mixture was heated to 75° C. under a nitrogen environment and maintained for 30 min. 1 g of triphosgene was dissolved in 20 mL of anhydrous ethyl acetate and added to the above reaction solution. The reaction was carried out for about 5 h until the solution became clear and transparent. Subsequently, the clear solution was rotary evaporated and precipitated with excess hexane. Finally, the obtained powder was placed in a vacuum drying oven and the water was drained to obtain the product.

[0124] (3) Preparation of dopamine-polylysine: 500 mg of lysine monomer, 10.32 mg of dopamine hydrochloride and 12.55 μL of triethylamine were dissolved in anhydrous N,N-dimethylformamide and reacted at 40° C. in a nitrogen environment for 24 h. The obtained product was dialyzed to remove impurities and freeze-dried to obtain dopamine-polylysine;

[0125] (4) Preparation of dopamine-polylysine-polyethylene glycol-maleimide: 100 mg of dopamine-polylysine with a degree of polymerization of 100 and 25.56 mg of active ester-polyethylene glycol-maleimide were dissolved in N,N-dimethylformamide solution, reacted at room temperature for 24 h, the obtained product was dialyzed to remove impurities, and freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide;

[0126] (5) Method for removing lysine protecting groups from dopamine-polylysine-polyethylene glycol-maleimide: 500 mg of dopamine-polylysine-polyethylene glycol-maleimide was dissolved in 2 mL of trifluoroacetic acid, and then 1506.1 μL of hydrobromic acid was added. The mixture was reacted at room temperature for 2 h, and chloroform was added. The trifluoroacetic acid was removed by rotary evaporation, and the mixture was dissolved in N,N-dimethylformamide. Impurities were removed by dialysis, and the mixture was freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide with positive charges after removing the protecting groups.

[0127] (6) Preparation of superparamagnetic particles modified by cationic polymers: 2 mg of the superparamagnetic particles obtained in step (1) were dissolved in 10 mL of chloroform, 10 mg of the dopamine-polylysine-polyethylene glycol-maleimide with positive charge removed from the protecting group obtained in step (5) was dissolved in 500 μL of dimethyl sulfoxide, the two solutions were mixed, and the mixture was vigorously shaken at room temperature for 4 h. After the reaction was completed, the solvent was dried under nitrogen atmosphere, the mixture was placed in a vacuum drying oven to drain the residual solvent, and 1 mL of aqueous solution was added for re-dissolution to obtain superparamagnetic nanoparticles modified by cationic polymers;

[0128] (7) Preparation of superparamagnetic particles with brain targeting function: 1 mL of the cationic polymer-modified superparamagnetic nanoparticles obtained in step (6) was added with 80 mg of thiol-modified RVG29, and the mixture was reacted at room temperature for 24 h. The product was dialyzed to remove impurities, thereby obtaining superparamagnetic particles with brain targeting function;

[0129] (8) Construction of a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function: 0.50 μg of the superparamagnetic particles with targeting function obtained in step (7) was mixed with 1 μg of CRISPR / Cas9 plasmid (px458 plasmid) and allowed to stand for 30 min to obtain a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function.

[0130] Example 3

[0131] This embodiment provides a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function, and its preparation method is as follows:

[0132] (1) Preparation of superparamagnetic nanoparticles: 0.400 g of 4-bibenzoic acid, 0.706 g of iron (III) acetylacetonate, 1.270 g of oleic acid and 19 mL of benzyl ether were mixed together in a three-necked round-bottom flask, the solution was heated to 120°C and kept in a nitrogen environment for 15 min, then the mixed solution was heated to 320°C at a rate of 20°C / min and aged for 90 min. After the solution was cooled, the solution was washed with methanol, and superparamagnetic nanoparticles with better magnetic properties were selected and dissolved in chloroform;

[0133] (2) Preparation of lysine monomer: 2 g of H-Lys(Z)-OH was dissolved in 80 mL of anhydrous ethyl acetate in a three-necked flask, and the mixture was heated to 75° C. under a nitrogen environment and maintained for 30 min. 1 g of triphosgene was dissolved in 20 mL of anhydrous ethyl acetate and added to the above reaction solution. The reaction was carried out for about 5 h until the solution became clear and transparent. Subsequently, the clear solution was rotary evaporated and precipitated with excess hexane. Finally, the obtained powder was placed in a vacuum drying oven and the water was drained to obtain the product.

[0134] (3) Preparation of dopamine-polylysine: 500 mg of lysine monomer, 3.5 mg of dopamine hydrochloride and 2.6 μL of triethylamine were dissolved in anhydrous N,N-dimethylformamide and reacted at 40° C. in a nitrogen environment for 24 h. The obtained product was dialyzed to remove impurities and freeze-dried to obtain dopamine-polylysine;

[0135] (4) Preparation of dopamine-polylysine-polyethylene glycol-maleimide: 100 mg of dopamine-polylysine with a degree of polymerization of 150 and 8.8 mg of active ester-polyethylene glycol-maleimide were dissolved in N,N-dimethylformamide solution, reacted at room temperature for 24 h, the obtained product was dialyzed to remove impurities, and freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide;

[0136] (5) Method for removing lysine protecting groups from dopamine-polylysine-polyethylene glycol-maleimide: 500 mg of dopamine-polylysine-polyethylene glycol-maleimide was dissolved in 2 mL of trifluoroacetic acid, and then 508.6 μL of hydrobromic acid was added, and the mixture was reacted at room temperature for 2 h. Chloroform was added, and the trifluoroacetic acid was removed by rotary evaporation. The mixture was dissolved in N,N-dimethylformamide, and impurities were removed by dialysis. The mixture was freeze-dried to obtain dopamine-polylysine-polyethylene glycol-maleimide with positively charged protecting groups.

[0137] (6) Preparation of superparamagnetic particles modified by cationic polymers: 2 mg of the superparamagnetic particles obtained in step (1) were dissolved in 10 mL of chloroform, 10 mg of the dopamine-polylysine-polyethylene glycol-maleimide with positive charge removed from the protecting group obtained in step (5) was dissolved in 500 μL of dimethyl sulfoxide, the two solutions were mixed, and the mixture was vigorously shaken at room temperature for 4 h. After the reaction was completed, the solvent was dried under nitrogen atmosphere, the mixture was placed in a vacuum drying oven to drain the residual solvent, and 1 mL of aqueous solution was added for re-dissolution to obtain superparamagnetic nanoparticles modified by cationic polymers;

[0138] (7) Preparation of superparamagnetic particles with brain targeting function: 1 mL of the cationic polymer-modified superparamagnetic nanoparticles obtained in step (6) was added with 120 mg of thiol-modified RVG29, and the mixture was reacted at room temperature for 24 h. The product was dialyzed to remove impurities, thereby obtaining superparamagnetic particles with brain targeting function;

[0139] (8) Construction of a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function: 0.10 μg of the superparamagnetic particles with targeting function obtained in step (7) was mixed with 1 μg of CRISPR / Cas9 plasmid (px458 plasmid) and allowed to stand for 30 min to obtain a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function.

[0140] Experimental Example 1 Detection of changes in infrared spectra of superparamagnetic nanoparticles before and after brain-targeted molecular modification

[0141] The superparamagnetic nanoparticles prepared in step (1) of Example 1 and the superparamagnetic nanoparticles with brain targeting function obtained in step (7) were subjected to infrared detection. Figure 3 As shown, the superparamagnetic particles with brain targeting function obtained in step (7) show characteristic absorption peaks of hydroxyl and carbonyl groups compared with the superparamagnetic nanoparticles prepared in step (1), indicating that the brain targeting molecules are successfully modified on the surface of the superparamagnetic nanoparticles.

[0142] Experimental Example 2: Detecting the ability of a CRISPR / Cas9 delivery system with both MRI tracing and brain targeting functions to load CRISPR / Cas9 plasmids

[0143] 0, 0.03125 μg, 0.0625 μg, 0.125 μg, 0.25 μg, 0.5 μg and 1 μg of the superparamagnetic particles with targeting function obtained in step (7) of Example 1 were electrostatically adsorbed with 1 μg of CRISPR / Cas9 plasmid, respectively. After standing for 30 minutes, the adsorption capacity of the system for CRISPR / Cas9 plasmid was detected by 1% agarose gel electrophoresis. The results are as follows Figure 4 As shown, 0.25 μg of superparamagnetic particles with targeting function obtained in step (7) of Example 1 can completely adsorb 1 μg of CRISPR / Cas9 plasmid, indicating that the system has a strong plasmid adsorption ability.

[0144] Experimental Example 3: Detection of the particle size and potential of the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function

[0145] 50 μL of the delivery system with both MRI tracing function and brain targeting function without adsorbing CRISPR / Cas9 plasmid and 50 μL of the delivery system with both MRI tracing function and brain targeting function after adsorbing CRISPR / Cas9 plasmid were dissolved in 1 mL of aqueous solution, respectively, to prepare samples for particle size and potential detection, and the potential was measured using a Nano-ZS90 laser particle size analyzer. The potential results are shown in Figure 5 As shown, the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function prepared in Example 2 exhibits a high positive charge of about +44mV before loading the CRISPR / Cas9 plasmid, and exhibits electrical neutrality of about +4mV after loading the CRISPR / Cas9 plasmid, indicating that the CRISPR / Cas9 plasmid is successfully adsorbed on the superparamagnetic particles. The particle size was measured using a Nano-ZS90 laser particle size analyzer, with the refractive index set to 1.590, the absorption coefficient set to 0.010, the temperature set to 25°C, the measurement mode set to automatic, and the Z average statistical value as the measurement result. The particle size results are shown in Figure 6 As shown, the particle size of the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function prepared in Example 3 is about 67 nm.

[0146] Experimental Example 4: Detection of relaxation efficiency

[0147] The relaxivity of magnetic nanoparticles is a key parameter affecting magnetic resonance imaging. To further analyze the relaxivity of the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function prepared in Example 1, a 1.5Telsa nuclear magnetic resonance instrument was used to measure the spin-spin relaxation time (T2) at different iron ion concentrations. The relaxation efficiency r2 was obtained by calculating the slope of the linear regression curve of the relaxation rate R2 (R2 = 1 / T2) and the iron ion concentration. Figure 7 As shown in Figure 1, the relaxation efficiency of the CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function prepared in Example 1 reached 450.13 mM -1 s -1 , significantly superior to commercially available magnetic iron oxide nanoparticle contrast agents and has excellent MRI imaging sensitivity.

[0148] Experimental Example 5 Detection of in vivo MRI tracing function

[0149] The CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function prepared in Experimental Example 1 was injected into mice through the tail vein. Brain magnetic resonance imaging was performed using a 7Telas magnetic resonance imaging instrument 12 hours later. The results are as follows: Figure 8As shown, there are obvious MR signals in the brains of mice injected with the CRISPR / Cas9 delivery system that has both MRI tracing and brain targeting functions, indicating that the system can successfully achieve the tracing function.

[0150] In summary, the present invention creatively designs and prepares a CRISPR / Cas9 delivery system with both MRI tracing function and brain targeting function, directly utilizes MRI contrast agent to efficiently load CRISPR / Cas9 plasmid, and through the modification of targeting molecules, enables the delivery system to be specifically enriched in the lesion and improves the relaxation rate of the delivery system, providing an efficient drug delivery platform for traceable gene therapy of brain-related diseases.

[0151] The present invention illustrates the detailed method of the present invention through the above-mentioned embodiments, but the present invention is not limited to the above-mentioned detailed method, that is, it does not mean that the present invention must rely on the above-mentioned detailed method to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention. Sequence Listing <110> Institute of Process Engineering, Chinese Academy of Sciences <120> A CRISPR / Cas9 delivery system and its preparation method and application <130> 20210308 <160> 1 <170> SIPOSequenceListing 1.0 <210> 1 <211> 29 <212> PRT <213> Artificial Sequence() <400> 1 Tyr Thr Ile Trp Met Pro Glu Asn Pro Arg Pro Gly Thr Pro Cys Asp 1 5 10 15 Ile Phe Thr Asn Ser Arg Gly Lys Arg Ala Ser Asn Gly 20 25

Claims

1. A method for preparing a CRISPR / Cas9 delivery system, characterized in that: The delivery system comprises superparamagnetic nanoparticles, cationic polymers, targeting molecules and CRISPR / Cas9 plasmids, wherein the cationic polymers are attached to the superparamagnetic nanoparticles, the targeting molecules and the CRISPR / Cas9 plasmids are respectively combined with the cationic polymers, the cationic polymers are dopamine-polylysine-polyethylene glycol-maleimide, the targeting molecules are polypeptides derived from rabies virus glycoproteins, the amino acid sequence of the polypeptides derived from rabies virus glycoproteins is shown in SEQ ID NO: 1, and the targeting molecules are treated with thiol modification; The preparation method of the CRISPR / Cas9 delivery system comprises the following steps: (1) mixing a cationic polymer with superparamagnetic nanoparticles and reacting them to obtain superparamagnetic particles modified with the cationic polymer; (2) mixing the cationic polymer-modified superparamagnetic particles with targeting molecules to react and obtain superparamagnetic particles with targeting function; (3) mixing the CRISPR / Cas9 plasmid with the superparamagnetic particles with targeting function, reacting to obtain the CRISPR / Cas9 delivery system; The method for preparing the CRISPR / Cas9 delivery system further includes the step of preparing a cationic polymer, comprising the following steps: (1') using benzyloxycarbonyl-protected lysine to react under the action of triphosgene to obtain a lysine monomer; (2') using dopamine hydrochloride as an initiator to initiate a ring-opening reaction of the lysine monomer obtained in step (1') and polymerize to form dopamine-polylysine; (3') mixing active ester-polyethylene glycol-maleimide with the dopamine-polylysine obtained in step (2') to react to obtain dopamine-polylysine-polyethylene glycol-maleimide; (4') in an acidic environment, removing the benzyloxycarbonyl protecting group of lysine from the dopamine-polylysine-polyethylene glycol-maleimide synthesized in step (3') to obtain the cationic high molecular polymer; The preparation method of the CRISPR / Cas9 delivery system also includes the step of preparing superparamagnetic nanoparticles. The preparation method of the superparamagnetic nanoparticles includes mixing biphenyl-4-carboxylic acid, tris(2,4-pentanedione)iron(III), oleic acid and benzyl ether, reacting to obtain superparamagnetic nanoparticles.

2. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The mass ratio of the cationic high molecular polymer and the superparamagnetic nanoparticles mixed in step (1) is 1:(5-20).

3. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (1) is 20-30°C.

4. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction time of step (1) is 2 to 6 hours.

5. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The mass ratio of the cationic polymer-modified superparamagnetic particles to the targeting molecules in step (2) is (10-100):

1.

6. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The solvent for the reaction in step (2) is water.

7. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (2) is 20-30°C.

8. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction time of step (2) is 24 to 48 hours.

9. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: In step (3), the mass ratio of the CRISPR / Cas9 plasmid to the superparamagnetic particles with targeting function is (0.1-10):

1.

10. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (3) is 20-30°C.

11. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction time of step (3) is 10 to 40 minutes.

12. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: Step (1') is to mix benzyloxycarbonyl-protected lysine and anhydrous ethyl acetate, and then add triphosgene to react to obtain lysine monomer.

13. The method for preparing the CRISPR / Cas9 delivery system according to claim 12, characterized in that: The ratio of the benzyloxycarbonyl protected lysine to anhydrous ethyl acetate is 1 g: (30-100) mL.

14. The method for preparing the CRISPR / Cas9 delivery system according to claim 12, characterized in that: The mass ratio of the benzyloxycarbonyl-protected lysine to triphosgene is (1-3):

1.

15. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (1') is 60-75°C.

16. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction time of step (1') is 4 to 5 hours.

17. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: Step (2') is to mix dopamine hydrochloride, lysine monomer and triethylamine in anhydrous N,N-dimethylformamide and react to obtain dopamine-polylysine.

18. The method for preparing the CRISPR / Cas9 delivery system according to claim 17, characterized in that: The mass ratio of the lysine monomer to dopamine hydrochloride is (1-100):

1.

19. The method for preparing the CRISPR / Cas9 delivery system according to claim 17, characterized in that: The molar ratio of the triethylamine to dopamine hydrochloride is (1-3):

1.

20. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The polymerization degree of the dopamine-polylysine polymer is any integer between 1 and 500.

21. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (2') is 40-50°C.

22. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction time of step (2') is 20 to 25 hours.

23. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The molar ratio of the active ester-polyethylene glycol-maleimide to dopamine-polylysine in step (3') is (1-3):

1.

24. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The solvent for the reaction in step (3') is N,N-dimethylformamide.

25. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The reaction temperature in step (3') is 20-30°C.

26. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The acidic environment in step (4') is a mixed solution of trifluoroacetic acid and hydrobromic acid.

27. The method for preparing the CRISPR / Cas9 delivery system according to claim 26, characterized in that: The mass ratio of trifluoroacetic acid to hydrobromic acetic acid is (5-20):

1.

28. The method for preparing the CRISPR / Cas9 delivery system according to claim 26, characterized in that: The mass ratio of the hydrogen bromide acetic acid to dopamine-lysine-polyethylene glycol-maleimide is (1-100):

1.

29. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The mass ratio of biphenyl-4-carboxylic acid and tris(2,4-pentanedione)iron(III) is (0.5-0.6):

1.

30. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The mass ratio of oleic acid to tri(2,4-pentanedione)iron(III) is (1.7-1.8):

1.

31. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The ratio of the benzyl ether to tri(2,4-pentanedione)iron(III) is (26-27) mL:1 g.

32. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: In the step of preparing superparamagnetic nanoparticles, the reaction is heated to 110-130°C, nitrogen is introduced for 10-20 minutes, and then the temperature is raised to 280-300°C.

33. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: In the step of preparing superparamagnetic nanoparticles, the reaction time is 1 to 2 hours.

34. The method for preparing the CRISPR / Cas9 delivery system according to claim 1, characterized in that: The preparation method of the CRISPR / Cas9 delivery system comprises the following steps: (1) biphenyl-4-carboxylic acid, tri(2,4-pentanedione)iron(III), oleic acid and benzyl ether are mixed in a ratio of (0.5-0.6) g:1 g:(1.7-1.8) g:(26-27) mL, the temperature is first raised to 110-130° C., nitrogen is introduced for 10-20 min, and the temperature is then raised to 280-300° C. for reaction for 1-2 h to obtain superparamagnetic nanoparticles; (2) mixing benzyloxycarbonyl protected lysine and anhydrous ethyl acetate in a ratio of 1 g: (30-100) mL, and then adding triphosgene, wherein the mass ratio of the benzyloxycarbonyl protected lysine to triphosgene is (1-3):1, and reacting at 60-75° C. for 4-5 hours to obtain a lysine monomer; (3) mixing dopamine hydrochloride, lysine monomer and triethylamine in anhydrous N,N-dimethylformamide, wherein the mass ratio of the lysine monomer to dopamine hydrochloride is (1-100):1, and the molar ratio of the triethylamine to dopamine hydrochloride is (1-3):1, and reacting at 40-50° C. for 20-25 hours to obtain dopamine-polylysine; (4) in N,N-dimethylformamide, the active ester-polyethylene glycol-maleimide and the dopamine-polylysine are mixed in a molar ratio of (1-3):1, and reacted at 20-30° C. to obtain dopamine-polylysine-polyethylene glycol-maleimide; (5) removing the benzyloxycarbonyl protecting group of lysine from the dopamine-polylysine-polyethylene glycol-maleimide in a mixed solution of trifluoroacetic acid and hydrobromic acid in a mass ratio of (5 to 20):1 to obtain the cationic polymer; (6) mixing the cationic polymer and the superparamagnetic nanoparticles at a mass ratio of 1:(5-20), reacting at 20-30° C. for 2-6 hours, to obtain superparamagnetic particles modified with the cationic polymer; (7) mixing the cationic polymer-modified superparamagnetic particles with the targeting molecules at a mass ratio of (10-100):1, and reacting at 20-30° C. for 24-48 hours to obtain superparamagnetic particles with targeting function; (8) Mixing the CRISPR / Cas9 plasmid and the superparamagnetic particles with targeting function at a mass ratio of (0.1-10):1, reacting at 20-30° C. for 10-40 minutes, and obtaining the CRISPR / Cas9 delivery system.

Citation Information

Patent Citations

  • High polymer in-situ modified super-paramagnetic particle, and preparation method and use thereof

    CN103405790A

  • Superparamagnetic particles targeting rheumatoid arthritis part as well as preparation method and application of particles

    CN103690971A

  • CRISPR / Cas9 delivery system and preparing method and application thereof

    CN110215522A

  • Application of poly-dopamine composite magnetic micro-nano particles in oily sewage treatment

    CN104098156A

  • Superparamagnetism nanoparticles, preparation method therefor and applications

    CN104906600A